HRP20150836T1 - Antagonisti specifiäśni za fgf-r4 receptor - Google Patents
Antagonisti specifiäśni za fgf-r4 receptor Download PDFInfo
- Publication number
- HRP20150836T1 HRP20150836T1 HRP20150836TT HRP20150836T HRP20150836T1 HR P20150836 T1 HRP20150836 T1 HR P20150836T1 HR P20150836T T HRP20150836T T HR P20150836TT HR P20150836 T HRP20150836 T HR P20150836T HR P20150836 T1 HRP20150836 T1 HR P20150836T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- fgf
- treatment
- receptor
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims 3
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 claims 13
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims 13
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 230000003042 antagnostic effect Effects 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (19)
1. Protutijelo antagonist receptor-specifičnog faktora rasta fibroblasta 4 (FGF-R4) naznačeno time da je za uporabu za liječenje bolesti povezanih sa patološkom angiogenezom.
2. Protutijelo prema zahtjevu 1, naznačeno time da je za uporabu kod inhibicije rasta tumora istovremeno s inhibicijom angiogeneze.
3. Protutijelo prema bilo kojem od zahtjeva 1 i 2, naznačeno time da je za uporabu za liječenje hepatokarcinoma ili bilo koje druge vrste raka jetre.
4. Protutijelo prema jednom od zahtjeva 1 do 3, naznačeno time da je za uporabu za liječenje raka gušterače.
5. Protutijelo za uporabu prema jednom od zahtjeva 1 do 4, naznačeno time da se veže na D2-D3 domenu FGF-R4 receptora.
6. Protutijelo za uporabu prema jednom od zahtjeva 1 do 5, naznačeno time da se veže na D2 domenu FGF-R4 receptora.
7. Protutijelo za uporabu prema jednom od zahtjeva 1 do 6, naznačeno time da ima KD s obzirom na FGF-R4 receptor, određen pomoću tehnike rezonancije površinskih plazmona (Biacore), od manje od 10-8 M.
8. Protutijelo za uporabu prema jednom od zahtjeva 1 do 7, naznačeno time da je aktivno i protiv ljudskog FGF-R4 i protiv mišjeg FGF-R4.
9. FGF-R4 receptor-specifično antagonističko protutijelo koje sadrži CDR-ove za sekvence SEQ ID br.: 9, 10, 11, 12, 13 i 14; ili 73, 74, 75, 78, 79 i 80; ili 83, 84, 85, 88, 89 i 90; ili 93, 94, 95, 98, 99 i 100; ili 103, 104, 105, 108, 109 i 110, gdje se jedan od CDR-ova može razlikovati za jednu ili dvije amino kiseline kada se uspoređuje s barem jednom od gore navedenih sekvenci, pod uvjetom da protutijelo zadržava svoju specifičnost vezanja, za uporabu za liječenje bolesti povezanih s patološkom angiogenezom.
10. FGF-R4 receptor-specifično antagonističko protutijelo čija varijabilna regija njegovog teškog lanca sadrži nukleotidnu sekvencu koja ima barem 80% identičnosti sa sekvencom SEQ ID br.: 5, 76, 86, 96 ili 106 i čija varijabilna regija njegovog lakog lanca sadrži nukleotidnu sekvencu koja ima barem 80% identičnosti sa sekvencom SEQ ID NO: 7, 71, 81, 91 ili 101, pod uvjetom da protutijelo zadržava svoju specifičnost vezanja, naznačeno time da je za uporabu za liječenje bolesti povezanih s patološkom angiogenezom.
11. FGF-R4 receptor-specifično antagonističko protutijelo, čija sekvenca sadrži sekvence polipeptida SEQ ID br.: 2 i 4; ili 6 i 8; ili 72 i 77; ili 82 i 87; ili 92 i 97; ili 102 i 107 ili sekvence, koje odgovaraju ovim sekvencama, koje imaju barem 80% identičnosti sa njima, pod uvjetom da protutijelo zadržava svoju specifičnost vezanja, naznačeno time da je za uporabu za liječenje bolesti povezanih s patološkom angiogenezom.
12. FGF-R4 receptor-specifično protutijelo za uporabu prema bilo kojem od zahtjeva 1 do 11, naznačeno time da je humanizirano protutijelo.
13. Protutijelo za uporabu prema zahtjevu 12, naznačeno time da sadrži varijabilni laki lanac koji ima barem 80% identičnosti sa jednom od polipeptidnih sekvenci SEQ ID NO: 30 ili 32 i varijabilni teški lanac koji ima barem 80% identičnosti sa sekvencama SEQ ID NO: 34, 36 ili 38.
14. Protutijelo za uporabu prema jednom od zahtjeva 1 do 13, naznačeno time da je protutijelo koje je konjugirano na citotoksično sredstvo.
15. Protutijelo prema jednom od zahtjeva 9 do 14, naznačeno time da je za uporabu za inhibiciju proliferacije stanica tumora za liječenje hepatokarcinoma ili bilo koje druge vrste raka jetre, te za liječenje raka gušterače.
16. Farmaceutski pripravak koji sadrži protutijelo prema bilo kojem od zahtjeva 1 do 15 i pomoćna sredstva, naznačeno time da je za uporabu za liječenje bolesti povezanih sa patološkom angiogenezom.
17. Lijek koji sadrži protutijelo prema bilo kojem od zahtjeva 1 do 16, naznačen time da je za uporabu za liječenje bolesti povezanih sa patološkom angiogenezom.
18. Polinukleotid koji kodira FGF-R4 receptor-specifični antagonist polipeptida, čije sekvence imaju barem 80% identičnosti s jednom od slijedećih sekvenci: SEQ ID br.: 2 i 4; ili SEQ ID br.: 6 i 8; ili SEQ ID br.: 9, 10, 11, 12, 13 i 14; ili SEQ ID br.: 30 ili 32 i 34 ili 36 ili 38; ili SEQ ID br.: 72 i 77; ili SEQ ID br.: 73, 74, 75, 78, 79 i 80; ili SEQ ID br.: 82 i 87; ili SEQ ID br.: 83, 84, 85, 88, 89 i 90; ili SEQ ID br.: 92 i 97; ili SEQ ID br.: 93, 94, 95, 98, 99 i 100; ili SEQ ID br.: 102 i 107; ili SEQ ID br.: 103, 104, 105, 108, 109 i 110, pod uvjetom da polipeptid koji ona kodira zadržava specifičnost vezanja, naznačen time da je za uporabu za liječenje bolesti povezanih sa patološkom angiogenezom.
19. Polinukleotid naznačen time da ima sekvencu koja ima barem 80% identičnosti s jednom od sekvenci SEQ ID br.: 1 i 3; ili SEQ ID br.: 5 i 7; SEQ ID br.: 29 ili 31, i 33, 35 ili 37; ili SEQ ID br.: 71 i 76; ili SEQ ID br.: 81 i 86; ili SEQ ID br.: 91 i 96; ili SEQ ID br.: 101 i 106, pod uvjetom da polipeptid koji ona kodira zadržava specifičnost antagonističkog vezanja na FGF-R4 receptor, te je za uporabu za liječenje bolesti povezanih sa patološkom angiogenezom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0803888A FR2933702A1 (fr) | 2008-07-08 | 2008-07-08 | Antagonistes specifiques du recepteur fgf-r4 |
EP09784478.1A EP2315781B1 (fr) | 2008-07-08 | 2009-07-07 | Antagonistes specifiques du recepteur fgf-r4 |
PCT/FR2009/051343 WO2010004204A2 (fr) | 2008-07-08 | 2009-07-07 | Antagonistes specifiques du recepteur fgf-r4 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150836T1 true HRP20150836T1 (hr) | 2015-09-11 |
Family
ID=40626849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150836TT HRP20150836T1 (hr) | 2008-07-08 | 2015-08-06 | Antagonisti specifiäśni za fgf-r4 receptor |
Country Status (38)
Country | Link |
---|---|
US (1) | US20110150903A1 (hr) |
EP (1) | EP2315781B1 (hr) |
JP (2) | JP5726731B2 (hr) |
KR (1) | KR20110028536A (hr) |
CN (2) | CN103784954A (hr) |
AR (1) | AR072699A1 (hr) |
AU (1) | AU2009267834B2 (hr) |
BR (1) | BRPI0915660A2 (hr) |
CA (1) | CA2730300A1 (hr) |
CL (1) | CL2011000047A1 (hr) |
CO (1) | CO6440535A2 (hr) |
CR (1) | CR11868A (hr) |
CY (1) | CY1116847T1 (hr) |
DK (1) | DK2315781T3 (hr) |
DO (1) | DOP2011000005A (hr) |
EA (2) | EA021580B1 (hr) |
EC (1) | ECSP11010748A (hr) |
ES (1) | ES2544761T3 (hr) |
FR (1) | FR2933702A1 (hr) |
HK (1) | HK1159133A1 (hr) |
HN (1) | HN2011000074A (hr) |
HR (1) | HRP20150836T1 (hr) |
HU (1) | HUE027221T2 (hr) |
IL (1) | IL210516A0 (hr) |
MA (1) | MA32547B1 (hr) |
MX (1) | MX2011000328A (hr) |
NI (1) | NI201100012A (hr) |
NZ (2) | NZ590860A (hr) |
PE (1) | PE20110313A1 (hr) |
PL (1) | PL2315781T3 (hr) |
PT (1) | PT2315781E (hr) |
SG (1) | SG10201403751XA (hr) |
SI (1) | SI2315781T1 (hr) |
TW (1) | TW201006492A (hr) |
UA (1) | UA107782C2 (hr) |
UY (1) | UY31970A (hr) |
WO (1) | WO2010004204A2 (hr) |
ZA (1) | ZA201100209B (hr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011139985A1 (en) * | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US8906649B2 (en) | 2010-09-27 | 2014-12-09 | Janssen Biotech, Inc. | Antibodies binding human collagen II |
EP2621950A4 (en) * | 2010-09-27 | 2015-09-02 | Janssen Biotech Inc | ANTIBODIES FOR BINDING HUMAN COLLAGEN II |
MX342240B (es) | 2011-04-07 | 2016-09-21 | Genentech Inc | Anticuerpos anti-fgfr4 y metodos de uso. |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
US20140294820A1 (en) * | 2011-06-24 | 2014-10-02 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
SG10201806648TA (en) | 2011-07-01 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Compositions, uses and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9963494B2 (en) | 2012-11-28 | 2018-05-08 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CN105008548B (zh) | 2012-12-27 | 2020-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法 |
WO2014105849A1 (en) * | 2012-12-28 | 2014-07-03 | Xoma (Us) Llc | Antibodies specific for fgfr4 and methods of use |
WO2014165287A1 (en) * | 2013-03-12 | 2014-10-09 | The Translational Genomics Research Institute | Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4 |
US9957313B2 (en) | 2013-03-15 | 2018-05-01 | Remegen, Ltd. | FGFR-FC fusion proteins and the use thereof |
SG11201602183QA (en) | 2013-10-25 | 2016-05-30 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
MX2016004822A (es) | 2013-10-28 | 2016-08-17 | Ngm Biopharmaceuticals Inc | Modelos de cancer y metodos asociados. |
TW201612518A (en) * | 2014-01-17 | 2016-04-01 | Sanofi Sa | Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody |
LT3097122T (lt) | 2014-01-24 | 2020-07-27 | Ngm Biopharmaceuticals, Inc. | Antikūnai, surišantys beta kloto domeną 2, ir jų panaudojimo būdai |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
CA2951153A1 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
TR201909951T4 (tr) | 2014-07-18 | 2019-07-22 | Sanofi Sa | Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem. |
CN104177492B (zh) * | 2014-07-21 | 2017-02-22 | 暨南大学 | FGFR2c胞外段类似物及其编码基因与应用 |
PL3180356T3 (pl) * | 2014-08-11 | 2020-04-30 | Daiichi Sankyo Europe Gmbh | Ludzkie przeciwciało anty-fgfr4 |
EP3200786B1 (en) | 2014-10-03 | 2019-08-28 | Novartis AG | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
IL251834B2 (en) | 2014-10-23 | 2023-09-01 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions containing peptide variants and methods of using them |
WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
CA2976766A1 (en) | 2015-03-25 | 2016-09-29 | Novartis Ag | Formylated n-heterocyclic derivatives as fgfr4 inhibitors |
EP3095465A1 (en) | 2015-05-19 | 2016-11-23 | U3 Pharma GmbH | Combination of fgfr4-inhibitor and bile acid sequestrant |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
CA3003616C (en) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
CN108602890A (zh) | 2015-12-11 | 2018-09-28 | 瑞泽恩制药公司 | 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法 |
EP3414267B1 (en) | 2016-02-10 | 2023-12-27 | BioInvent International AB | Combination of human anti-fgfr4 antibody and sorafenib |
MX2018010485A (es) * | 2016-03-04 | 2019-01-10 | Jn Biosciences Llc | Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit). |
AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
RU2742033C2 (ru) | 2016-11-02 | 2021-02-01 | Новартис Аг | Комбинации ингибиторов fgfr4 и секвестрантов желчных кислот |
JP7265476B2 (ja) * | 2016-11-22 | 2023-04-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Fgfr1を対象とするモノクローナル抗体 |
EP3444275A1 (en) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
CN109725159B (zh) * | 2018-12-28 | 2021-10-08 | 江苏众红生物工程创药研究院有限公司 | 人β2-微球蛋白的定量检测试纸卡与临床应用 |
CN115551538A (zh) * | 2020-01-21 | 2022-12-30 | 拓维创新生物科技(香港)有限公司 | 干扰IL-1β受体信号转导的药剂 |
WO2021247591A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
WO2022098662A2 (en) * | 2020-11-03 | 2022-05-12 | Twist Bioscience Corporation | Methods and compositions relating to chemokine receptor variants |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO2001049698A1 (en) * | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
EP2229955A1 (en) * | 2003-10-16 | 2010-09-22 | Imclone LLC | Fibroblast growth factor receptor-1 inhibitors and methods of treatment using the same |
US7678373B2 (en) * | 2006-02-10 | 2010-03-16 | Genentech, Inc. | Anti-FGF19 antibodies and methods using same |
EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
JP5570218B2 (ja) * | 2006-11-03 | 2014-08-13 | ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Fgfr4抗体 |
MX2009009574A (es) * | 2007-03-09 | 2009-09-16 | Novartis Ag | Tratamiento de melanoma. |
-
2008
- 2008-07-08 FR FR0803888A patent/FR2933702A1/fr active Pending
-
2009
- 2009-07-07 EP EP09784478.1A patent/EP2315781B1/fr not_active Not-in-force
- 2009-07-07 ES ES09784478.1T patent/ES2544761T3/es active Active
- 2009-07-07 CN CN201410084647.7A patent/CN103784954A/zh active Pending
- 2009-07-07 UA UAA201101398A patent/UA107782C2/ru unknown
- 2009-07-07 SI SI200931242T patent/SI2315781T1/sl unknown
- 2009-07-07 EA EA201170155A patent/EA021580B1/ru not_active IP Right Cessation
- 2009-07-07 NZ NZ590860A patent/NZ590860A/xx not_active IP Right Cessation
- 2009-07-07 NZ NZ602905A patent/NZ602905A/en not_active IP Right Cessation
- 2009-07-07 PL PL09784478T patent/PL2315781T3/pl unknown
- 2009-07-07 AR ARP090102534A patent/AR072699A1/es unknown
- 2009-07-07 CA CA2730300A patent/CA2730300A1/fr not_active Abandoned
- 2009-07-07 DK DK09784478.1T patent/DK2315781T3/en active
- 2009-07-07 WO PCT/FR2009/051343 patent/WO2010004204A2/fr active Application Filing
- 2009-07-07 BR BRPI0915660A patent/BRPI0915660A2/pt not_active IP Right Cessation
- 2009-07-07 EA EA201401107A patent/EA201401107A1/ru unknown
- 2009-07-07 HU HUE09784478A patent/HUE027221T2/en unknown
- 2009-07-07 AU AU2009267834A patent/AU2009267834B2/en not_active Ceased
- 2009-07-07 MX MX2011000328A patent/MX2011000328A/es active IP Right Grant
- 2009-07-07 US US13/002,845 patent/US20110150903A1/en not_active Abandoned
- 2009-07-07 SG SG10201403751XA patent/SG10201403751XA/en unknown
- 2009-07-07 KR KR1020117002857A patent/KR20110028536A/ko not_active Application Discontinuation
- 2009-07-07 JP JP2011517203A patent/JP5726731B2/ja not_active Expired - Fee Related
- 2009-07-07 PT PT97844781T patent/PT2315781E/pt unknown
- 2009-07-07 CN CN200980134842.3A patent/CN102149730B/zh not_active Expired - Fee Related
- 2009-07-07 PE PE2011000015A patent/PE20110313A1/es not_active Application Discontinuation
- 2009-07-08 UY UY0001031970A patent/UY31970A/es not_active Application Discontinuation
- 2009-07-08 TW TW098123091A patent/TW201006492A/zh unknown
-
2010
- 2010-12-22 CR CR11868A patent/CR11868A/es not_active Application Discontinuation
-
2011
- 2011-01-06 IL IL210516A patent/IL210516A0/en unknown
- 2011-01-06 DO DO2011000005A patent/DOP2011000005A/es unknown
- 2011-01-07 ZA ZA2011/00209A patent/ZA201100209B/en unknown
- 2011-01-07 HN HN2011000074A patent/HN2011000074A/es unknown
- 2011-01-07 CO CO11001540A patent/CO6440535A2/es active IP Right Grant
- 2011-01-07 CL CL2011000047A patent/CL2011000047A1/es unknown
- 2011-01-07 EC EC2011010748A patent/ECSP11010748A/es unknown
- 2011-01-07 NI NI201100012A patent/NI201100012A/es unknown
- 2011-02-08 MA MA33595A patent/MA32547B1/fr unknown
- 2011-12-21 HK HK11113762.6A patent/HK1159133A1/xx not_active IP Right Cessation
-
2014
- 2014-10-17 JP JP2014212724A patent/JP2015057398A/ja active Pending
-
2015
- 2015-08-05 CY CY20151100681T patent/CY1116847T1/el unknown
- 2015-08-06 HR HRP20150836TT patent/HRP20150836T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150836T1 (hr) | Antagonisti specifiäśni za fgf-r4 receptor | |
KR102128966B1 (ko) | 종양 투과성 펩타이드와 항-신생혈관생성 제제가 융합된 융합단백질을 유효성분으로 포함하는 암 또는 혈관신생관련 질환 예방 및 치료용 약학적 조성물 | |
HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
JP2018520650A5 (hr) | ||
MX2013007936A (es) | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta. | |
HRP20181646T2 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
HRP20211346T1 (hr) | Kombinirani pripravci za liječenje raka | |
HRP20230078T1 (hr) | Sredstva za vezivanje vegf/dll4 i njihova uporaba | |
JP2018502051A5 (hr) | ||
JP2017506217A5 (hr) | ||
RU2022108079A (ru) | Антитело против garp | |
JP2015532644A5 (hr) | ||
JP2014158469A5 (hr) | ||
RU2012126138A (ru) | Специфические связывающие агенты против в7-н1 | |
JP2009525764A5 (hr) | ||
JP2016529215A5 (hr) | ||
JP2011526891A5 (hr) | ||
RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
HRP20161736T1 (hr) | Protutijelo koje prepoznaje čimbenik inhibicije ljudske leukemije (lif) i upotreba protutijela protiv lif u liječenju bolesti povezanih s nepoželjnom staničnom proliferacijom | |
JP2017101068A5 (hr) | ||
HRP20131107T1 (hr) | Anti-notch1 nrr-protutijela i postupak njihove uporabe | |
RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
FI3036258T3 (fi) | Immunoreseptorin modulointi syövän ja virusinfektioiden hoitamiseksi | |
WO2014012007A4 (en) | Rspo3 binding agents and uses thereof |